A Phase 3 interventional study of tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-01.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 75th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 83rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 99th largest by enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2014, is one of 85 in phase 3, and was the 182nd registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open-label, single-arm study will evaluate the efficacy, safety and tolerability of subcutaneously administered tocilizumab in monotherapy and/or in combination with methotrexate and other non-biologic disease modifying anti-rheumatic drug (DMARDs) in participants with active rheumatoid arthritis (RA) who are naïve to tocilizumab. Participants will receive tocilizumab 162 milligram (mg) subcutaneously weekly for 24 weeks. Participants who complete the core study achieving at least a moderate European League Against Rheumatism (EULAR) response at Week 24 may enter the extension phase and receive for a further 28 weeks at the most.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
Drug: tocilizumab
Fixed dose of 162 mg subcutaneously weekly
Also known as: RoActemra/Actemra
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Full Analysis Set (FAS)
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.
Time frame: From baseline to Week 24
Change From Baseline in Disease Activity Score 28 - Erythrocyte Sedimentation Rate (DAS28-ESR) Score in the Per Protocol Set (PPS)
The DAS28 score is a measure of the participant's disease activity calculated using the TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS and acute phase reactant (ESR or CRP) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.
Time frame: From baseline to Week 24
Percentage of Participants With Positive American College of Rheumatology (ACR) Response Scores
The ACR core set of outcome measures and their definition of improvement includes a \>= 20% improvement (ACR20) compared to Baseline in both SJC and TJC as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, PGA VAS, patient's assessment of pain VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and acute phase reactant (CRP or ESR). VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Achievement of an ACR50 requires a \>= 50% improvement in the same parameters and an ACR70 requires a \>= 70% improvement.
Time frame: From Baseline to Week 2, Week 24, and Week 52
Percentage of Participants With Responses According to European League Against Rheumatism (EULAR ) Criteria
EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline \>1.2 with a DAS28 score of \<=3.2; moderate responders = decrease from baseline \>1.2 with a DAS28 score of \>3.2, or decrease from baseline \>0.6 to \<=1.2 with a DAS28 score of \<=5.1; non-responders = decrease from baseline \<=0.6 or decrease from baseline \>0.6 and \<=1.2 with a DAS28 score of \>5.1.
Time frame: From Baseline to Week 2, Week 24
Change From Baseline in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)
SDAI is a similar index to DAS28 but has the advantage of not needing a complicated mathematical formula for its determination, but a simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. CDAI does not incorporate an acute response, therefore it can be used to evaluate disease activity in the absence of laboratory testing of CRP and ESR. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. SDAI scores ranged from 0 to 86, CDAI from 0 to 76 with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change in Total Tender/Swollen Joint Counts (TJC/SJC)
An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation
Time frame: Up to Week 52
Percentage of Participants Achieving CDAI Remission, CDAI Low Disease Activity, Moderate Disease Activity and High Disease Activity
CDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total CDAI score ranges from 0 to 76 with higher scores indicating increased disease activity. Clinical remission = score ≤ 2.8; Low disease activity = score \> 2.8 and ≤ 10.0; Moderate disease activity = score \> 10.0 and ≤ 22.0; High disease activity = score \> 22.0.
Time frame: Baseline to Week 2, Week 24 and Week 52
Percentage of Participants Achieving SDAI Remission, SDAI LDA, Moderate Disease Activity and High Disease Activity
SDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total SDAI score ranges from 0 to 86 with higher scores indicating increased disease activity. Clinical remission = score ≤ 3.3; Low disease activity = score \> 3.3 and ≤ 11.0; Moderate disease activity = score \> 11.0 and ≤ 26.0; high disease activity = score \> 26.0.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Percentage of Participants Achieving DAS28-ESR Remission, DAS28-ESR LDA, Moderate Disease Activity and High Disease Activity
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. Clinical remission = score \<2.6; Low disease activity = score ≥2.6 and ≤3.2; Moderate disease activity = score \> 3.2 and ≤5.1; High disease activity = score \>5.1.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Percentage of Participants Achieving a Clinically Significant Improvement in DAS28
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Physician's Global Assessment of Disease Activity VAS
Physician's Global Assessment of disease activity VAS represents the physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100= "maximum disease activity". This was completed by the Treating Physician (or designee). A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Patient's Global Assessment of Disease Activity VAS
PGA VAS represents the participant's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100="maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Patient's Assessment of Pain VAS
Patient's Assessment of Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no pain" and the extreme right end 100="unbearable pain". A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2 and Week 24
Acute Phase Reactants: Change From Baseline in CRP
A negative change from baseline in CRP level indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Acute Phase Reactants: Change From Baseline in ESR
A negative change from baseline in ESR indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)
The symptom-specific measure FACIT-F was developed to assess chronic illness therapy with special emphasis on fatigue in the past 7 days. In this study, only the FACIT-F short questionnaire, which is a shorter version of the initial FACIT-F questionnaire, was used. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. The 13 items included in the FACIT-F short can be used to calculate the brief score for FACIT-F scale (score range: 0-52). A positive change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The participant self-rates each of these seven areas of sleep. Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Global scores range from 0 to 21 and a global sum of "5" or greater indicates a "poor" sleeper. Although there are several questions that request the evaluation of the participant's bed mate or roommate, these are not scored. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 4, Week 24 and Week 52
Change From Baseline in Patient Quality of Sleep VAS
The Patient Quality of Sleep VAS assessment represents the participant's assessment of his/her current quality of sleep on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no difficulty to sleep" and the extreme right end 100="extreme sleeping difficulties". A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Arthritis Impact Measurement Scale-Short Form (AIMS-SF)
The AIMS-SF is a reduced version of the validated AIMS2 questionnaire. The Short Form has been developed using a comprehensive expert-based approach and supported by psychometric testing. The AIMS-SF is a self-administered questionnaire to measure changes in global health, pain, mobility and social function in adult patients with arthritis and reports scores for physical, symptoms, affect, social and work assessments. Scores range from 0 to 10, higher scores indicating higher impact of arthritis on the assessments. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 4, Week 24 and Week 52
Change From Baseline in Patient Fatigue VAS
The Patient Fatigue VAS assessment represents the participant's assessment of his/her current level of fatigue on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no fatigue" and the extreme right end 100="extreme fatigue". A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Patient Satisfaction VAS
The Patient Satisfaction VAS assessment represents the participant's assessment of his/her current satisfaction with treatment on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no satisfaction" and the extreme right end 100="extremely satisfied". A positive change from baseline indicates an improvement.
Time frame: From Baseline to Week 2, Week 24 and Week 52
Change From Baseline in Work Instability Scale for Rheumatoid Arthritis (RA-WIS)
The 23-item RA-WIS is a simple, validated screening tool for work instability, i.e., the consequences of a mismatch between an individual's functional ability and their work tasks. This self-administered questionnaire covers a broad range of specific work-related issues and enables monitoring the risk of work disability in rheumatoid arthritis patients. The RA-WIS is scored by summing responses from all 23 scale items. The scale ranges from 0 to 23. Cut points have been established to differentiate levels of work instability: low \< 10, moderate 10-17 and high \> 17. A negative change from baseline indicates an improvement.
Time frame: From Baseline to Week 24
Treatment Satisfaction Questionnaire for Medication (TSQM ) Scores
The abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) derived from the TSQM Version 1.4 but without the five items of the side effects domain, is a reliable and valid measure to assess participants' satisfaction with treatment. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Domains included are effectiveness, convenience and global satisfaction.
Time frame: Week 24
Safety: Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Up to 52 weeks
Safety: Percentage of Participants With Anti-tocilizumab Antibodies
Time frame: Baseline, Week 24
| Milestone | Tocilizumab |
|---|---|
| Started | 57 |
| Completed | 46 |
| Not completed | 11 |
| Withdrew: Adverse event | 6 |
| Withdrew: Participant decision to withdraw | 2 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Insufficient therapeutic response | 1 |
| Withdrew: Hypersensitivity reaction | 1 |
| Milestone | Tocilizumab |
|---|---|
| Started | 39 |
| Completed | 37 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Insufficient therapeutic response | 1 |
The DAS28 score is a measure of the participant's disease activity calculated using the tender joint count of 28 joints (TJC28), swollen joint count of 28 joints (SJC28), patient's global assessment of disease activity visual analog scale (PGA VAS) with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=56) | 5.55 ± 1.17 |
| Change at Week 24 (n=42) | -3.24 ± 1.47 |
The DAS28 score is a measure of the participant's disease activity calculated using the TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS and acute phase reactant (ESR or CRP) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n= 27) | 5.73 ± 1.33 |
| Change at Week 24 (n= 20) | -3.21 ± 1.42 |
The ACR core set of outcome measures and their definition of improvement includes a \>= 20% improvement (ACR20) compared to Baseline in both SJC and TJC as well as in three out of five additional parameters: Physician's Global Assessment of disease activity VAS, PGA VAS, patient's assessment of pain VAS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and acute phase reactant (CRP or ESR). VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Achievement of an ACR50 requires a \>= 50% improvement in the same parameters and an ACR70 requires a \>= 70% improvement.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline: ACR 20 (n=55) | 0 |
| Week 2: ACR 20 (n=51) | 21.6 |
| Week 24: ACR 20 (n=39) | 84.6 |
| Week 52: ACR 20 (n=8) | 100 |
| Baseline: ACR 50 (n=55) | 0 |
| Week 2: ACR 50 (n=52) | 1.9 |
| Week 24: ACR 50 (n=39) | 66.7 |
| Week 52: ACR 50 (n=8) | 62.5 |
| Baseline: ACR 70 (n=55) | 0 |
| Week 2: ACR 70 (n=52) | 0 |
| Week 24: ACR 70 (n=39) | 38.5 |
| Week 52: ACR 70 (n=8) | 25.0 |
EULAR response was calculated as the difference between DAS28-ESR scores at baseline and Week 24, and reported as the percentage of participants with good, moderate, or no response. Good responders = decrease from baseline \>1.2 with a DAS28 score of \<=3.2; moderate responders = decrease from baseline \>1.2 with a DAS28 score of \>3.2, or decrease from baseline \>0.6 to \<=1.2 with a DAS28 score of \<=5.1; non-responders = decrease from baseline \<=0.6 or decrease from baseline \>0.6 and \<=1.2 with a DAS28 score of \>5.1.
| percentage of participants | Tocilizumab |
|---|---|
| Week 2: Good response (n=56) | 17.9 |
| Week 24: Good response (n=42) | 76.2 |
| Week 2: Moderate response (n=56) | 50.0 |
| Week 24: Moderate response (n=42) | 19.0 |
| Week 2: No response (n=56) | 32.1 |
| Week 24: No response (n=42) | 4.8 |
SDAI is a similar index to DAS28 but has the advantage of not needing a complicated mathematical formula for its determination, but a simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. CDAI does not incorporate an acute response, therefore it can be used to evaluate disease activity in the absence of laboratory testing of CRP and ESR. VAS range for all assessments was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. SDAI scores ranged from 0 to 86, CDAI from 0 to 76 with higher scores indicating increased disease activity. A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=53) | 33.26 ± 13.50 |
| Change at Week 2: SDAI (n=52) | -9.00 ± 11.89 |
| Change at Week 24: SDAI (n=38) | -25.33 ± 13.63 |
| Change at Week 52: SDAI (n=7) | -34.04 ± 16.01 |
| Baseline: CDAI (n= 55) | 31.86 ± 12.60 |
| Change at Week 2: CDAI (n=55) | -7.61 ± 11.51 |
| Change at Week 24: CDAI (n=42) | -23.55 ± 13.03 |
| Change at Week 52: CDAI (n=8) | -29.99 ± 13.89 |
An assessment of 66 joints for swelling and 68 joints for tenderness was made. Joints were assessed and classified as swollen/not swollen and tender/not tender by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. A negative change from baseline indicates an improvement.
| Joint Counts | Tocilizumab |
|---|---|
| Baseline: TJC (n=53) | 16.02 ± 11.77 |
| Change at Week 2: TJC (n=53) | -3.58 ± 8.91 |
| Change at Week 24: TJC (n=41) | -12.10 ± 11.07 |
| Change at Week 52: TJC (n=8) | -17.25 ± 13.02 |
| Baseline: SJC (n=55) | 10.20 ± 7.14 |
| Change at Week 2: SJC (n=55) | -3.93 ± 7.33 |
| Change at Week 24: SJC (n=42) | -9.81 ± 7.84 |
| Change at Week 52: SJC (n=8) | -11.75 ± 7.76 |
| percentage of participants | Tocilizumab |
|---|---|
| Percentage of Participants With Corticosteroid Dose Reduction/Discontinuation | 50.0 |
CDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total CDAI score ranges from 0 to 76 with higher scores indicating increased disease activity. Clinical remission = score ≤ 2.8; Low disease activity = score \> 2.8 and ≤ 10.0; Moderate disease activity = score \> 10.0 and ≤ 22.0; High disease activity = score \> 22.0.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline: Clinical remission (n=55) | 0 |
| Week 2: Clinical remission (n=56) | 1.8 |
| Week 24: Clinical remission (n=43) | 30.2 |
| Week 52: Clinical remission (n=8) | 37.5 |
| Baseline: Low disease activity (n=55) | 0 |
| Week 2: Low disease activity (n=56) | 7.1 |
| Week 24: Low disease activity (n=43) | 34.9 |
| Week 52: Low disease activity (n=8) | 25.0 |
| Baseline: Moderate disease activity (n=55) | 21.8 |
| Week 2: Moderate disease activity (n=56) | 48.2 |
| Week 24: Moderate disease activity (n=43) | 30.2 |
| Week 52: Moderate disease activity (n=8) | 37.5 |
| Baseline: High disease activity (n=55) | 78.2 |
| Week 2: High disease activity (n=56) | 42.9 |
| Week 24: High disease activity (n=43) | 4.7 |
| Week 52: High disease activity (n=8) | 0 |
SDAI is calculated by simple arithmetical addition of TJC28 and SJC28, PGA VAS and Physician Global Assessment of disease activity VAS, and CRP concentration in mg/L. VAS range was 0=no disease activity to 100=maximum disease activity displayed on the 100-mm horizontal VAS. Total SDAI score ranges from 0 to 86 with higher scores indicating increased disease activity. Clinical remission = score ≤ 3.3; Low disease activity = score \> 3.3 and ≤ 11.0; Moderate disease activity = score \> 11.0 and ≤ 26.0; high disease activity = score \> 26.0.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline: Clinical remission (n=53) | 0 |
| Week 2: Clinical remission (n=55) | 1.8 |
| Week 24: Clinical remission (n=40) | 30.0 |
| Week 52: Clinical remission (n=7) | 42.9 |
| Baseline: Low disease activity (n=53) | 0 |
| Week 2: Low disease activity (n=55) | 7.3 |
| Week 24: Low disease activity (n=40) | 40.0 |
| Week 52: Low disease activity (n=7) | 14.3 |
| Baseline: Moderate disease activity (n=53) | 30.2 |
| Week 2: Moderate disease activity (n=55) | 54.5 |
| Week 24: Moderate disease activity (n=40) | 25.0 |
| Week 52: Moderate disease activity (n=7) | 42.9 |
| Baseline: High disease activity (n=53) | 69.8 |
| Week 2: High disease activity (n=55) | 36.4 |
| Week 24: High disease activity (n=40) | 5.0 |
| Week 52: High disease activity (n=7) | 0 |
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. Clinical remission = score \<2.6; Low disease activity = score ≥2.6 and ≤3.2; Moderate disease activity = score \> 3.2 and ≤5.1; High disease activity = score \>5.1.
| percentage of participants | Tocilizumab |
|---|---|
| Baseline: Clinical remission (n=56) | 0 |
| Week 2: Clinical remission (n=56) | 7.1 |
| Week 24: Clinical remission (n=42) | 64.3 |
| Week 52: Clinical remission (n=8) | 87.5 |
| Baseline: Low disease activity (n=56) | 1.8 |
| Week 2: Low disease activity (n=56) | 16.1 |
| Week 24: Low disease activity (n=42) | 16.7 |
| Week 52: Low disease activity (n=8) | 0 |
| Baseline: Moderate disease activity (n=56) | 35.7 |
| Week 2: Moderate disease activity (n=56) | 53.6 |
| Week 24: Moderate disease activity (n=42) | 19.0 |
| Week 52: Moderate disease activity (n=8) | 12.5 |
| Baseline: High disease activity (n=56) | 62.5 |
| Week 2: High disease activity (n=56) | 23.2 |
| Week 24: High disease activity (n=42) | 0 |
| Week 52: High disease activity (n=8) | 0 |
The DAS28 score is a measure of the participant's disease activity calculated using TJC28, SJC28, PGA VAS with 0=no disease activity to 100=maximum disease activity displayed on the 100-millimeter (mm) horizontal VAS and acute phase reactant (erythrocyte sedimentation rate \[ESR\] or C-reactive protein \[CRP\]) for a total possible score of 0 to 10. For this study ESR was used to calculate the DAS28 score. The index is calculated using the following formula: DAS28 = (0.56\*√\[TJC28\]) + (0.28\*√\[SJC28\]) + (0.70\*ln\[ESR\]) + (0.014\*VAS). Higher scores represent higher disease activity. DAS28 Clinically Significant Improvement was defined as a DAS28 score reduction of at least 1.2 units from Baseline.
| percentage of participants | Tocilizumab |
|---|---|
| Week 2 (n=56) | 66.1 |
| Week 24 (n=42) | 90.5 |
| Week 52 (n=8) | 100 |
Physician's Global Assessment of disease activity VAS represents the physician's assessment of the participant's current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100= "maximum disease activity". This was completed by the Treating Physician (or designee). A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=56) | 64.93 ± 17.73 |
| Change at Week 2 (n=56) | -16.34 ± 16.88 |
| Change at Week 24 (n=45) | -48.93 ± 25.06 |
| Change at Week 52 (n=9) | -57.44 ± 23.26 |
PGA VAS represents the participant's overall assessment of their current disease activity on a 100 mm horizontal VAS. The extreme left end of the line represents 0= "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end 100="maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=57) | 67.28 ± 22.25 |
| Change at Week 2 (n=57) | -11.82 ± 23.23 |
| Change at Week 24 (n=46) | -36.02 ± 29.38 |
| Change at Week 52 (n=9) | -44.78 ± 35.87 |
Patient's Assessment of Pain VAS represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no pain" and the extreme right end 100="unbearable pain". A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=57) | 66.77 ± 21.43 |
| Change at Week 2 (n=57) | -11.32 ± 19.74 |
| Change at Week 24 (n=46) | -35.37 ± 27.03 |
| Change at Week 52 (n=9) | -49.33 ± 39.58 |
A negative change from baseline in CRP level indicates an improvement.
| milligrams per liter (mg/L) | Tocilizumab |
|---|---|
| Baseline (n=55) | 13.79 ± 20.78 |
| Change at Week 2 (n=54) | -13.19 ± 20.64 |
| Change at Week 24 (n=42) | -10.12 ± 14.50 |
| Change at Week 52 (n=8) | -25.07 ± 23.03 |
A negative change from baseline in ESR indicates an improvement.
| millimeters per hour (mm/hr) | Tocilizumab |
|---|---|
| Baseline (n=56) | 33.75 ± 28.90 |
| Change at Week 2 (n=55) | -19.95 ± 18.22 |
| Change at Week 24 (n=44) | -22.80 ± 24.88 |
| Change at Week 52 (n=9) | -27.78 ± 23.82 |
The Stanford HAQ-DI is a patient-oriented outcome assessment questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other common activities. Each category contains multiple questions, which were answered using a 4-point scale from 0 to 3. The overall index score was an average of the individual item responses and may range from 0 to 3, where higher scores indicate more difficulty in daily living activities. A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=57) | 1.44 ± 0.68 |
| Change at Week 2 (n=57) | -0.08 ± 0.43 |
| Change at Week 24 (n=46) | -0.54 ± 0.68 |
| Change at Week 52 (n=9) | -1.33 ± 0.68 |
The symptom-specific measure FACIT-F was developed to assess chronic illness therapy with special emphasis on fatigue in the past 7 days. In this study, only the FACIT-F short questionnaire, which is a shorter version of the initial FACIT-F questionnaire, was used. Each of the questions is categorically answered using the scales 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. The figures are reversed during score calculations, so that higher score values indicate more favorable conditions. The 13 items included in the FACIT-F short can be used to calculate the brief score for FACIT-F scale (score range: 0-52). A positive change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=57) | 26.09 ± 10.75 |
| Change at Week 2 (n=57) | 2.32 ± 9.58 |
| Change at Week 24 (n=45) | 10.53 ± 12.06 |
| Change at Week 52 (n=9) | 20.89 ± 12.35 |
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over 1-month time interval. Nineteen individual items generate seven "component" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The participant self-rates each of these seven areas of sleep. Scoring of answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. Global scores range from 0 to 21 and a global sum of "5" or greater indicates a "poor" sleeper. Although there are several questions that request the evaluation of the participant's bed mate or roommate, these are not scored. A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=57) | 8.81 ± 4.39 |
| Change at Week 4 (n=54) | -1.24 ± 3.53 |
| Change at Week 24 (n=46) | -2.63 ± 4.14 |
| Change at Week 52 (n=9) | -4.56 ± 5.88 |
The Patient Quality of Sleep VAS assessment represents the participant's assessment of his/her current quality of sleep on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no difficulty to sleep" and the extreme right end 100="extreme sleeping difficulties". A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=57) | 54.95 ± 31.23 |
| Change at Week 2 (n=57) | -8.40 ± 23.72 |
| Change at Week 24 (n=46) | -21.93 ± 30.87 |
| Change at Week 52 (n=9) | -34.22 ± 37.03 |
The AIMS-SF is a reduced version of the validated AIMS2 questionnaire. The Short Form has been developed using a comprehensive expert-based approach and supported by psychometric testing. The AIMS-SF is a self-administered questionnaire to measure changes in global health, pain, mobility and social function in adult patients with arthritis and reports scores for physical, symptoms, affect, social and work assessments. Scores range from 0 to 10, higher scores indicating higher impact of arthritis on the assessments. A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline: Physical (n= 49) | 3.57 ± 1.92 |
| Change at Week 4: Physical (n= 47) | -0.57 ± 1.36 |
| Change at Week 24: Physical (n=38) | -1.41 ± 1.83 |
| Change at Week 52: Physical (n=3) | -3.62 ± 2.23 |
| Baseline: Symptom (50) | 6.33 ± 2.59 |
| Change at Week 4: Symptom (n= 48) | -1.15 ± 2.46 |
| Change at Week 24: Symptom (n=40) | -2.69 ± 2.80 |
| Change at Week 52: Symptom (n=3) | -3.89 ± 5.91 |
| Baseline: Affect (n=50) | 5.07 ± 2.22 |
| Change at Week 4: Affect (n= 48) | -0.66 ± 1.56 |
| Change at Week 24: Affect (n=40) | -1.74 ± 2.22 |
| Change at Week 52: Affect (n=3) | -4.50 ± 2.22 |
| Baseline: Social (n=50) | 5.36 ± 1.73 |
| Change at Week 4: Social (n= 48) | 0.18 ± 1.41 |
| Change at Week 24: Social (n=40) | -0.56 ± 1.61 |
| Change at Week 52: Social (n=3) | -1.46 ± 2.37 |
| Baseline: Work (n=26) | 3.17 ± 2.46 |
| Change at Week 4: Work (n= 23) | -0.92 ± 2.53 |
| Change at Week 24: Work (n=21) | -0.65 ± 2.87 |
| Change at Week 52: Work (n=1) | 3.75 ± NA |
The Patient Fatigue VAS assessment represents the participant's assessment of his/her current level of fatigue on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no fatigue" and the extreme right end 100="extreme fatigue". A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=57) | 60.19 ± 24.79 |
| Change at Week 2 (n=57) | -3.74 ± 20.68 |
| Change at Week 24 (n=46) | -21.48 ± 28.07 |
| Change at Week 52 (n=9) | -50.89 ± 26.11 |
The Patient Satisfaction VAS assessment represents the participant's assessment of his/her current satisfaction with treatment on a 100 mm horizontal VAS. The extreme left end of the line represents 0="no satisfaction" and the extreme right end 100="extremely satisfied". A positive change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=53) | 39.66 ± 28.63 |
| Change at Week 2 (n=53) | 9.49 ± 33.97 |
| Change at Week 24 (n=43) | 33.07 ± 35.50 |
| Change at Week 52 (n=8) | 49.38 ± 35.12 |
The 23-item RA-WIS is a simple, validated screening tool for work instability, i.e., the consequences of a mismatch between an individual's functional ability and their work tasks. This self-administered questionnaire covers a broad range of specific work-related issues and enables monitoring the risk of work disability in rheumatoid arthritis patients. The RA-WIS is scored by summing responses from all 23 scale items. The scale ranges from 0 to 23. Cut points have been established to differentiate levels of work instability: low \< 10, moderate 10-17 and high \> 17. A negative change from baseline indicates an improvement.
| Units on a scale | Tocilizumab |
|---|---|
| Baseline (n=26) | 13.15 ± 6.05 |
| Change at Week 24 (n=22) | -3.55 ± 6.96 |
The abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) derived from the TSQM Version 1.4 but without the five items of the side effects domain, is a reliable and valid measure to assess participants' satisfaction with treatment. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction on that domain. Domains included are effectiveness, convenience and global satisfaction.
| Units on a scale | Tocilizumab |
|---|---|
| Effectiveness (n=46) | 66.7 ± 19.07 |
| Convenience (n=46) | 76.09 ± 15.66 |
| Global Satisfaction (n=46) | 65.06 ± 15.52 |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| percentage of participants | Tocilizumab |
|---|---|
| Safety: Percentage of Participants With Adverse Events | 96.5 |
| percentage of participants | Tocilizumab |
|---|---|
| Baseline (n= 55) | 0 |
| Week 24 (n= 43) | 1.7 |
Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 5/57 (8.8%) | 36/57 (63.2%) |
| Event | Tocilizumab |
|---|---|
| Atrial FlutterCardiac disorders | 1/57 |
| Diverticular perforationGastrointestinal disorders | 1/57 |
| HypersensitivityImmune system disorders | 1/57 |
| Arthritis InfectiveInfections and infestations | 1/57 |
| FallInjury, poisoning and procedural complications | 1/57 |
| Femur FractureInjury, poisoning and procedural complications | 1/57 |
| Chronic Lymphocytic LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/57 |
| Event | Tocilizumab |
|---|---|
| BronchitisInfections and infestations | 9/57 |
| NasopharyngitisInfections and infestations | 7/57 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/57 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 5/57 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 5/57 |
| VertigoEar and labyrinth disorders | 4/57 |
| NauseaGastrointestinal disorders | 4/57 |
| FatigueGeneral disorders | 4/57 |
| Urinary tract infectionInfections and infestations | 4/57 |
| Abdominal pain upperGastrointestinal disorders | 3/57 |
The full analysis set (FAS) consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 54.49 ± 11.08 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 44 |
| Male | 13 |
The record gives a start of Jan 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab